Pavla Stepankova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Pavla Stepankova has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Heidi Mocikova
Department of Hematology, Fakultni nemocnice Kralovske Vinohrady and 3rd Faculty of Medicine, Charles University, Prague, Czech Republic
1 shared publication - Jan Koren
First Medical Department - Clinical Department of Hematooncology, First Faculty of Medicine and General Teaching Hospital, Charles University in Prague, Prague
1 shared publication - Jana Markova
Department of Internal Medicine-Hematology, University Hospital Kralovske Vinohrady, Third Faculty of Medicine, Charles University, Prague, Czech Republic
1 shared publication - Jozef Michalka
Department of Internal Medicine, Hematology and Oncology University Hospital Brno Faculty of Medicine Masaryk University Brno Czech Republic
1 shared publication - Lucie Buresova
Department of Public Health, Faculty of Medicine, Masaryk University, Brno, Czech Republic
1 shared publication - Ludek Raida
Department of Hemato-Oncology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
1 shared publication
Latest Publications
- Open Access
- 1 March 2015
- Published by S. Karger AG in Acta Haematologica
- Vol. 134 (3) , 187-192
Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?
Background: Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma showing strong CD20 expression. The role of rituximab in treating NLPHL still needs clarification. Methods: We retrospectively reviewed the outcome of 23 patients with NLPHL treated with rituximab alone or in combination with chemotherapy and/or radiotherapy as part of their first- or second-line treatment. Results: The median follow-up of the whole group was 67 months, and all patients remained alive. Twenty-two patients achieved complete remission after rituximab-based therapy, and one of them relapsed 32 months after treatment. One patient treated with rituximab alone achieved partial remission and progressed 22 months after treatment. Conclusion: The prognosis of NLPHL is excellent. Rituximab combined with chemotherapy and/or radiotherapy appears to prevent disease progression/relapse.
- 1 March 2015
- Published by S. Karger AG in Acta Haematologica
- Vol. 134 (3) , 187-192
Open AccessCan Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?
Background: Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma showing strong CD20 expression. The role of rituximab in treating NLPHL still needs clarification. Methods: We retrospectively reviewed the outcome of 23 patients with NLPHL treated with rituximab alone or in combination with chemotherapy and/or radiotherapy as part of their first- or second-line treatment. Results: The median follow-up of the whole group was 67 months, and all patients remained alive. Twenty-two patients achieved complete remission after rituximab-based therapy, and one of them relapsed 32 months after treatment. One patient treated with rituximab alone achieved partial remission and progressed 22 months after treatment. Conclusion: The prognosis of NLPHL is excellent. Rituximab combined with chemotherapy and/or radiotherapy appears to prevent disease progression/relapse.